Literature DB >> 8892925

An in vivo mutation from leucine to tryptophan at position 210 in human immunodeficiency virus type 1 reverse transcriptase contributes to high-level resistance to 3'-azido-3'-deoxythymidine.

D J Hooker1, G Tachedjian, A E Solomon, A D Gurusinghe, S Land, C Birch, J L Anderson, B M Roy, E Arnold, N J Deacon.   

Abstract

Sequencing of the reverse transcriptase (RT) region of 26 human immunodeficiency virus type 1 (HIV-1) isolates from eight patients treated with 3'-azido-3'-deoxythymidine (AZT) revealed a mutation at codon 210 from TTG (leucine) to TGG (tryptophan) exclusively in association with resistance to AZT. The mutation Trp-210 was observed in 15 of the 20 isolates phenotypically resistant to AZT, being more commonly observed than resistance-associated mutations at codons 67, 70, and 219. Trp-210 was never observed before the emergence of resistance-associated mutations Leu-41 and Tyr-215, and in a sequential series of five isolates from one patient the order of emergence of mutations was found to be Tyr-215, Leu-41, and then Trp-210. Trp-210 was also found in association with the Leu-41, Asn-67, Arg-70, and Tyr-215 resistance genotype. To define the role of Trp-210 in AZT resistance, molecular HIV-1 clones were constructed with various combinations of RT mutations at codons 41, 67, 70, 210, and 215 and tested for susceptibility to AZT. In clones with polymerase genes derived either from HXB2-D or clinical isolates, Trp-210 alone did not increase AZT resistance, whereas in conjunction with Leu-41 and Tyr-215, Trp-210 contributed to high-level resistance (50% inhibitory concentration of >1 microM). In HXB2-D, Trp-210 with Tyr-215 generated a virus with resistance comparable to one with Leu-41, Tyr-215, and Trp-210. Inserting Trp-210 into the genetic context of mutations at codons 41, 67, 70, and 215 further enhanced resistance from a 50% inhibitory concentration of 1.44 microM to 8.41 microM. Molecular modeling of the tertiary structure of HIV-1 RT revealed that the distance between the side chains of Trp-210 (in helix alphaF) and Tyr-215 (in strand beta11a) approximated 4 A (1 A = 0.1 nm), sufficiently close to result in significant energetic interaction between these two aromatic side chains. In conclusion, Trp-210 contributes significantly to phenotypic AZT resistance of HIV-1 by augmenting resistance at least three- to sixfold in the context of two resistant genotypes, and its effect may require an interaction with an aromatic amino acid at position 215.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8892925      PMCID: PMC190874     

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   5.103


  55 in total

1.  pol mutations conferring zidovudine and didanosine resistance with different effects in vitro yield multiply resistant human immunodeficiency virus type 1 isolates in vivo.

Authors:  J J Eron; Y K Chow; A M Caliendo; J Videler; K M Devore; T P Cooley; H A Liebman; J C Kaplan; M S Hirsch; R T D'Aquila
Journal:  Antimicrob Agents Chemother       Date:  1993-07       Impact factor: 5.191

2.  A mutation in human immunodeficiency virus reverse transcriptase and decline in CD4 lymphocyte numbers in long-term zidovudine recipients.

Authors:  M J Kozal; R W Shafer; M A Winters; D A Katzenstein; T C Merigan
Journal:  J Infect Dis       Date:  1993-03       Impact factor: 5.226

3.  Crystal structure of human immunodeficiency virus type 1 reverse transcriptase complexed with double-stranded DNA at 3.0 A resolution shows bent DNA.

Authors:  A Jacobo-Molina; J Ding; R G Nanni; A D Clark; X Lu; C Tantillo; R L Williams; G Kamer; A L Ferris; P Clark
Journal:  Proc Natl Acad Sci U S A       Date:  1993-07-01       Impact factor: 11.205

4.  Rapid in vitro selection of human immunodeficiency virus type 1 resistant to 3'-thiacytidine inhibitors due to a mutation in the YMDD region of reverse transcriptase.

Authors:  M Tisdale; S D Kemp; N R Parry; B A Larder
Journal:  Proc Natl Acad Sci U S A       Date:  1993-06-15       Impact factor: 11.205

5.  Zidovudine treatment results in the selection of human immunodeficiency virus type 1 variants whose genotypes confer increasing levels of drug resistance.

Authors:  P Kellam; C A Boucher; J M Tijnagel; B A Larder
Journal:  J Gen Virol       Date:  1994-02       Impact factor: 3.891

6.  Human immunodeficiency virus type 1 pol gene mutations in an AIDS patient treated with multiple antiretroviral drugs.

Authors:  J E Fitzgibbon; A E Farnham; S J Sperber; H Kim; D T Dubin
Journal:  J Virol       Date:  1993-12       Impact factor: 5.103

7.  The safety and pharmacokinetics of a reverse transcriptase inhibitor, 3TC, in patients with HIV infection: a phase I study.

Authors:  R van Leeuwen; J M Lange; E K Hussey; K H Donn; S T Hall; A J Harker; P Jonker; S A Danner
Journal:  AIDS       Date:  1992-12       Impact factor: 4.177

8.  Zidovudine therapy and HIV encephalitis: a 10-year neuropathological survey.

Authors:  F Gray; L Bélec; C Keohane; P De Truchis; B Clair; M Durigon; A Sobel; R Gherardi
Journal:  AIDS       Date:  1994-04       Impact factor: 4.177

9.  Recombinant virus assay: a rapid, phenotypic assay for assessment of drug susceptibility of human immunodeficiency virus type 1 isolates.

Authors:  P Kellam; B A Larder
Journal:  Antimicrob Agents Chemother       Date:  1994-01       Impact factor: 5.191

10.  Sensitivity of wild-type human immunodeficiency virus type 1 reverse transcriptase to dideoxynucleotides depends on template length; the sensitivity of drug-resistant mutants does not.

Authors:  P L Boyer; C Tantillo; A Jacobo-Molina; R G Nanni; J Ding; E Arnold; S H Hughes
Journal:  Proc Natl Acad Sci U S A       Date:  1994-05-24       Impact factor: 11.205

View more
  41 in total

1.  Augmentation of human immunodeficiency virus type 1 subtype E (CRF01_AE) multiple-drug resistance by insertion of a foreign 11-amino-acid fragment into the reverse transcriptase.

Authors:  H Sato; Y Tomita; K Ebisawa; A Hachiya; K Shibamura; T Shiino; R Yang; M Tatsumi; K Gushi; H Umeyama; S Oka; Y Takebe; Y Nagai
Journal:  J Virol       Date:  2001-06       Impact factor: 5.103

2.  Antiretroviral Drug Resistance in HIV-1.

Authors: 
Journal:  Curr Infect Dis Rep       Date:  1999-08       Impact factor: 3.725

3.  Differences in the frequency of resistance to antiretroviral drug classes among human immunodeficiency virus type 1 clinical isolates.

Authors:  Rafael E Campo; Paola N Lichtenberger; Isabella Rosa; German Suarez; Fernando A Rivera; Allan E Rodriguez; Dushyantha T Jayaweera; Natalie A Wahlay; Michael A Kolber
Journal:  J Clin Microbiol       Date:  2003-07       Impact factor: 5.948

4.  A Guide to HIV-1 Reverse Transcriptase and Protease Sequencing for Drug Resistance Studies.

Authors:  Robert W Shafer; Kathryn Dupnik; Mark A Winters; Susan H Eshleman
Journal:  HIV Seq Compend       Date:  2001

5.  Chain-terminating dinucleoside tetraphosphates are substrates for DNA polymerization by human immunodeficiency virus type 1 reverse transcriptase with increased activity against thymidine analogue-resistant mutants.

Authors:  Peter R Meyer; Anthony J Smith; Suzanne E Matsuura; Walter A Scott
Journal:  Antimicrob Agents Chemother       Date:  2006-08-28       Impact factor: 5.191

Review 6.  Antiretroviral therapy : optimal sequencing of therapy to avoid resistance.

Authors:  Jorge L Martinez-Cajas; Mark A Wainberg
Journal:  Drugs       Date:  2008       Impact factor: 9.546

7.  The Genetic Basis of HIV-1 Resistance to Reverse Transcriptase and Protease Inhibitors.

Authors:  Robert W Shafer; Rami Kantor; Matthew J Gonzales
Journal:  AIDS Rev       Date:  2000       Impact factor: 2.500

8.  Detecting and understanding combinatorial mutation patterns responsible for HIV drug resistance.

Authors:  Jing Zhang; Tingjun Hou; Wei Wang; Jun S Liu
Journal:  Proc Natl Acad Sci U S A       Date:  2010-01-11       Impact factor: 11.205

9.  Sequence analysis of the polymerase domain of HIV-1 reverse transcriptase in naive and zidovudine-treated individuals reveals a higher polymorphism in alpha-helices as compared with beta-strands.

Authors:  L Medrano; L Menéndez-Arias; R De Jorge; M L Villahermosa; G Contreras; L Pérez-Alvarez; A Moya; R Nájera
Journal:  Virus Genes       Date:  1999       Impact factor: 2.332

10.  Coresistance to zidovudine and foscarnet is associated with multiple mutations in the human immunodeficiency virus type 1 reverse transcriptase.

Authors:  G Tachedjian; M French; J Mills
Journal:  Antimicrob Agents Chemother       Date:  1998-11       Impact factor: 5.191

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.